Informations sur le produit
- Zepsyre
- Spiro[6,16-(epithiopropanoxymethano)-7,13-imino-12H-1,3-dioxolo[7,8]isoquino[3,2-b][3]benzazocine-20,1'-[1H]pyrido[3,4-b]indol]-19-one, 5-(acetyloxy)-2',3',4',6,6a,7,9',13,14,16-decahydro-8,14-dihydroxy-6',9-dimethoxy-4,10,23-trimethyl-, (1'R,6R,6aR,7R,13S,14S,16R)- (9CI)
- Tryptamicidin
- PM 01183
- Spiro[6,16-(epithiopropanoxymethano)-7,13-imino-12H-1,3-dioxolo[7,8]isoquino[3,2-b][3]benzazocine-20,1′-[1H]pyrido[3,4-b]indol]-19-one, 5-(acetyloxy)-2′,3′,4′,6,6a,7,9′,13,14,16-decahydro-8,14-dihydroxy-6′,9-dimethoxy-4,10,23-trimethyl-, (1′R,6R,6aR,7R,13S,14S,16R)-
Lurbinectedin is a new drug that belongs to the class of DNA-interacting agents. It has been shown to be highly active against solid tumours and infectious diseases. Lurbinectedin inhibits the growth of cancer cells by binding to DNA, thereby preventing DNA synthesis and replication. The drug can be administered intravenously or intraperitoneally in the treatment of metastatic colorectal cancer. Lurbinectedin has also been shown to have potent antitumor activity against platinum-resistant ovarian cancer and platinum-based chemotherapy. Lurbinectedin binds to the ribosomal RNA of tumor cells and prevents the production of proteins vital for cell division. This drug is used as an adjuvant treatment in combination with other chemotherapeutic agents such as cisplatin or carboplatin for patients with metastatic colorectal cancer who are not responsive to standard chemotherapy treatments.
